Lupin Pharmaceuticals has announced that Maurice Chagnaud has joined the company as President, Europe and Head of Inhalation Strategy. He was most recently Senior Vice President, Central & Eastern Europe at Teva. Chagnaud’s responsibilities will include Lupin’s European business as well as the company’s “core strategy for inhalation in the developed markets.”
Lupin Limited CEO Vinita Gupta commented, “Over the years, Lupin has recorded consistent growth across advanced markets like the US and Japan. With Maurice’s rich experience we look forward to building our business in Europe, in particular around Complex Generics & Specialty. We are delighted to welcome him into the Lupin family.”
The company’s US division is also hiring for a number of inhalation positions.
Read the Lupin press release.
